| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TYROBP |
| Uniprot No | O43914 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-113aa |
| 氨基酸序列 | MGGLEPCSRLLLLPLLLAVSGLRPVQAQAQSDCSCSTVSPGVLAGIVMGD LVLTVLIALAVYFLGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSD VYSDLNTQRPYYK |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TYROBP重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *TYROBP (DAP12) regulates microglial phagocytosis and cytokine release in Alzheimer’s disease models*
**作者**: Smith, J. et al.
**摘要**: 本研究利用重组TYROBP蛋白体外处理小胶质细胞，发现其通过激活TREM2-DAP12信号通路增强β-淀粉样蛋白的吞噬能力，并抑制促炎因子释放，提示其在阿尔茨海默病中的治疗潜力。
---
2. **文献名称**: *Structural insights into TREM2-TYROBP complex assembly using recombinant co-expression system*
**作者**: Li, X. & Wang, Y.
**摘要**: 通过共表达重组TREM2和TYROBP蛋白，解析了二者复合物的晶体结构，揭示了TYROBP的跨膜结构域如何介导与TREM2的结合，为神经退行性疾病相关突变的功能研究提供结构基础。
---
3. **文献名称**: *Functional characterization of a novel TYROBP mutation linked to Nasu-Hakola disease*
**作者**: Tanaka, K. et al.
**摘要**: 研究在Nasu-Hakola病患者中发现TYROBP新突变，通过重组突变蛋白表达证实其损害与SIRPβ1受体的相互作用，导致破骨细胞信号传导异常，揭示了该疾病的分子机制。
---
**备注**：以上文献信息为模拟示例，实际引用时建议通过PubMed或Web of Science核对原文。如需进一步精准文献，可提供具体研究场景(如疾病方向或实验技术)。
TYROBP (TYRO protein tyrosine kinase-binding protein), also known as DAP12 (DNAX-activation protein 12), is a transmembrane signaling adaptor protein critical for immune receptor signaling in various immune cells. It contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, which mediates downstream signaling through phosphorylation by Src-family kinases. TYROBP interacts with cell-surface receptors lacking intrinsic signaling capacity, such as TREM (triggering receptor expressed on myeloid cells) family proteins, to regulate immune responses, including cytokine release, phagocytosis, and cell activation.
Originally identified in natural killer (NK) cells and myeloid cells, TYROBP-associated receptors play roles in neuroinflammation, osteoclast differentiation, and neurodegenerative diseases. Mutations in TYROBP are linked to Nasu-Hakola disease, a rare genetic disorder characterized by bone cysts and early-onset dementia, highlighting its importance in both immune and neural homeostasis.
Recombinant TYROBP proteins are engineered to study its structural and functional properties, often produced in mammalian or bacterial expression systems. These proteins retain the ITAM domain and transmembrane region, enabling in vitro investigations into receptor-ligand interactions, signaling cascades, and therapeutic targeting. Researchers utilize recombinant TYROBP to model pathological mechanisms, screen potential drugs, or develop biologics aimed at modulating immune responses in conditions like Alzheimer’s disease, multiple sclerosis, or osteoporosis. Its role as a universal adaptor makes it a focal point for understanding cross-talk between immune and non-immune systems.
×
